AI body scans could make chemo safer for women with gynecologic cancers
NCT ID NCT07144618
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 33 times
Summary
This study tests whether using AI to analyze CT scans of muscle mass can help doctors adjust chemotherapy doses to reduce side effects. About 294 women with endometrial or ovarian cancer will be split into two groups: one where the AI helps guide dosing, and one where standard dosing is used. The goal is to see if the AI approach lowers the risk of severe low white blood cell counts and other side effects, while also improving quality of life and reducing healthcare costs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cheng Kung University Hospital
Tainan, 704, Taiwan
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Paclitaxel (chemotherapy) with AI-assisted dose adjustment based on body composition from CT scans
What this could lead to
If successful, this could lead to a more personalized way to dose chemotherapy, reducing severe side effects like low white blood cell counts and improving quality of life for women with endometrial or ovarian cancer.
What could go wrong
This is a relatively early study (Phase 2) with 294 participants, so results may not apply to all patients. The AI tool's accuracy depends on CT scan quality, and adjusting doses might not always reduce side effects or could affect treatment effectiveness.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.